Biogen Inc. (BIIB) Guidance & Earnings Results

On 2026-07-29 Biogen Inc. raised guidance: "Full year 2026 guidance updated to reflect strengthening underlying business performance; Apellis acquisition expected ~$0.85 dilution to Non-GAAP diluted EPS for FY2026; accretive in 2027; run rate synergies exiting…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

BIIBBiogen Inc.Follow BIIB — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 37.0B
P/E TTM: 44.5
Dividend yield: —
52-week: —
Next earnings: 28 Oct, in 4 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
29 Jul 26	Raised	Full year 2026 guidance updated to reflect strengthening underlying business performance; Apellis acquisition expected ~$0.85 dilution to Non-GAAP diluted EPS for FY2026; accretive in 2027; run rate synergies exiting 2027 at least $250M. · full year
29 Apr 26	Mixed	FY2026 non-GAAP diluted EPS $14.25-$15.25; total revenue expected to decline mid-single digit % · full year
6 Feb 26	Mixed	FY2026 Non-GAAP diluted EPS $15.25-$16.25; total revenue decline mid-single digit % · full year
30 Oct 25	Raised	Non-GAAP EPS guidance raised to $14.50-$15.00; revenue growth guidance raised to flat to +1% · full year
31 Jul 25	Raised	FY2025 Non-GAAP diluted EPS raised to $15.50-$16.00 from $14.50-$15.50; FY2025 total revenue outlook improved to approximately flat (at constant currency) from mid-single digit decline · full year

Biogen Inc. — questions

What guidance did Biogen Inc. give?: On 2026-07-29: "Full year 2026 guidance updated to reflect strengthening underlying business performance; Apellis acquisition expected ~$0.85 dilution to Non-GAAP diluted EPS for FY2026; accretive in 2027; run rate synergies exiting 2027 at least $250M."
When does Biogen Inc. report earnings?: Biogen Inc.'s next earnings report is expected on 2026-10-28.

Every figure on this page comes from Biogen Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.